Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

The Tylenol poisonings allowed him an opportunity to prove his loyalty to the medical drug behemoth. Hayes “lost little time in publicly exonerating Johnson & Johnson,” writes Harris.

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

Johnson & Johnson, while primarily known as America's leading healthcare company, now employs nearly 7,000 digital specialists and data scientists.

Officials at the Department of Health and Human Services have struggled to find records belonging to Dr. Tom Shimabukuro, the director of the CDC’s Immunization Safety Office.